

Published in final edited form as:

*Neuron*. 2014 January 8; 81(1): 77–90. doi:10.1016/j.neuron.2013.10.052.

## Histidine decarboxylase deficiency causes Tourette syndrome: parallel findings in humans and mice

Lissandra Castellan Baldan, Ph.D.<sup>1</sup>, Kyle A. Williams, MD<sup>#1,2</sup>, Jean-Dominique Gallezot, Ph.D.<sup>#3</sup>, Vladimir Pogorelov, Ph.D.<sup>#1</sup>, Maximiliano Rapanelli, Ph.D.<sup>1</sup>, Michael Crowley, Ph.D.<sup>2</sup>, George M. Anderson, Ph.D.<sup>2,4</sup>, Erin Loring, MS<sup>2,5,8</sup>, Roxanne Gorczyca, MA<sup>10</sup>, Eileen Billingslea, MA<sup>1</sup>, Suzanne Wasylink, RNC<sup>1</sup>, Kaitlyn E. Panza, BA<sup>2</sup>, A. Gulhan Ercan-Sencicek, Ph.D.<sup>2,5</sup>, Kuakarun Krusong, Ph.D.<sup>1,11</sup>, Bennett L. Leventhal, MD<sup>12,13</sup>, Hiroshi Ohtsu, MD, Ph.D.<sup>14</sup>, Michael H. Bloch, MD, MS<sup>1,2</sup>, Zoë A. Hughes, Ph.D.<sup>10</sup>, John H. Krystal, MD<sup>1</sup>, Linda Mayes, MD<sup>1,2,6,7</sup>, Ivan de Araujo, Ph.D.<sup>1,15</sup>, Yu-Shin Ding, Ph.D.<sup>3,16</sup>, Matthew W. State, MD, Ph.D.<sup>1,2,5,8,17</sup>, and Christopher Pittenger, MD, Ph.D.<sup>1,2,7,9,\*</sup>

<sup>1</sup> Department of Psychiatry, Yale University School of Medicine <sup>2</sup> Department of Child Study Center, Yale University School of Medicine <sup>3</sup> Department of Diagnostic Radiology, Yale University School of Medicine <sup>4</sup> Department of Laboratory Medicine, Yale University School of Medicine <sup>5</sup> Department of Genetics, Yale University School of Medicine <sup>6</sup> Department of Pediatrics, Yale University School of Medicine <sup>7</sup> Department of Psychology, Yale University School of Medicine <sup>8</sup> Department of Program on Neurogenetics, Yale University School of Medicine <sup>9</sup> Integrated Neuroscience Research Program; New Haven, CT 06520 <sup>10</sup> Neuroscience Research Unit, Pfizer, Inc., Cambridge, MA <sup>11</sup> Dept. of Biochem., Faculty of Science, Chulalongkorn Univ., Bangkok, Thailand <sup>12</sup> Nathan S. Kline Institute for Psychiatric Research <sup>13</sup> New York University Dept of Child and Adolescent Psychiatry <sup>14</sup> Tohoku University, Graduate School of Engineering, Sendai, Japan <sup>15</sup> John B. Pierce Laboratory, New Haven, CT

# These authors contributed equally to this work.

### Abstract

Tourette syndrome (TS) is characterized by tics, sensorimotor gating deficiencies, and abnormalities of cortico-basal ganglia circuits. A mutation in histidine decarboxylase (*Hdc*), the key enzyme for the biosynthesis of histamine (HA), has been implicated as a rare genetic cause. *Hdc* knockout mice exhibited potentiated tic-like stereotypies, recapitulating core phenomenology of TS; these were mitigated by the dopamine D2 antagonist haloperidol, a proven pharmacotherapy, and by HA infusion into the brain. Prepulse inhibition was impaired in both mice and humans carrying *Hdc* mutations. HA infusion reduced striatal dopamine (DA) levels; in *Hdc* knockout mice, striatal DA was increased and the DA-regulated immediate early gene *Fos* was upregulated. Dopamine D2/D3 receptor binding was altered both in mice and in humans carrying the *Hdc* mutation. These data confirm HDC deficiency as a rare cause of TS and identify histamine-dopamine interactions in the basal ganglia as an important locus of pathology.

© 2013 Elsevier Inc. All rights reserved.

\* Correspondence: 34 Park Street, W315 New Haven, CT 06519 Christopher.pittenger@yale.edu.

<sup>16</sup>Current address: Department of Radiology, New York University, New York, NY

<sup>17</sup>Current address: Department of Psychiatry, UCSF, San Francisco, CA

**Publisher's Disclaimer:** This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

## INTRODUCTION

Tourette syndrome (TS) is characterized by pathognomic motor and vocal tics, as well as by sensory and cognitive symptoms. It affects 0.3-1.0% of the population. The onset of tics is typically in childhood; many patients, though not all, experience improvement of their symptoms in late adolescence or early adulthood.

Convergent evidence implicates dysregulation of cortico-basal ganglia circuits in TS (Albin, 2006; Leckman et al., 2010; Willms et al., 2013). Focal ischemic damage to the striatum, the input nucleus of the basal ganglia, can produce tics (Kwak and Jankovic, 2002), as can local striatal disinhibition in monkeys (McCairn et al., 2009). Disruption of dopaminergic modulation of this circuitry, in particular, is implicated, although the specific nature and etiology of this abnormality are unclear (Albin, 2006; Jankovic and Kurlan, 2011). PET imaging suggests increased striatal intrasynaptic dopamine (DA) in individuals with TS (Singer et al., 2002; Wong et al., 2008). The D2 dopamine receptor antagonists haloperidol and pimozide are the most efficacious pharmacological therapy for severe tics (Bloch, 2008; Du et al., 2010; Kurlan, 2010). Psychostimulant drugs such as D-amphetamine can trigger or worsen tics in patients (Leckman et al., 2010) and produce tic-like motor stereotypies in animals (Kelley, 2001).

The basal ganglia circuitry can be described, to a first approximation, as parallel cortico-striato-thalamo-cortical loops specialized for processing different types of behaviorally relevant information (Alexander et al., 1986; Choi et al., 2012; Haber and Knutson, 2010). Striatonigral neurons expressing the D1 dopamine receptor provide excitatory feedback to the cortex; striatopallidal neurons expressing the D2 dopamine receptor provide inhibitory feedback. Dynamic balance between these parallel pathways contributes to regulating diverse behaviors (Albin et al., 1989; Graybiel, 2008; Grillner et al., 2013; Haber and Knutson, 2010).

TS has a heritability of approximately 0.58 (Davis et al., 2013 (in press)). Causative mutations and major risk alleles have proven elusive (Bloch et al., 2011; O'Rourke et al., 2009; State, 2011). A recent genome-wide association study failed to identify any common polymorphisms with genome-wide statistical significance (Scharf et al., 2012). In this setting, rare, highly penetrant mutations are of particular value in the generation and testing of pathophysiological hypotheses.

A recent study of a 2-generation pedigree in a family with high incidence of TS identified a rare segregating nonsense mutation, *Hdc* W317X, in the *l-histidine decarboxylase* (*Hdc*) gene (Ercan-Sencicek et al., 2010). HDC is required for the generation of histamine (HA) from histidine (Haas et al., 2008). Subsequent analysis of copy number variation in TS also implicated disruption of histaminergic signaling (Fernandez et al., 2012). However, the causal connection between reduced HDC activity and TS symptoms, and the pathophysiological links between *Hdc* disruption and TS-relevant neurobiological abnormalities, remain unclear.

HA is produced by neurons in the tuberomammillary nucleus of the posterior hypothalamus that project throughout the central nervous system (CNS) (Haas et al., 2008). Pharmacological studies show that enhancing central HA production modulates stereotypy produced by methamphetamine (Joshi et al., 1981; Kitanaka et al., 2007) or apomorphine (Paul et al., 2000).

The *Hdc* W317X mutation is rare; it has not been identified outside of the index family (Ercan-Sencicek et al., 2010). However, it has several characteristics that make it optimal for testing in an animal model. It is dominantly acting and of high penetrance. The enzymatic

activity of HDC is well understood (Haas et al., 2008), and the nonsense mutation completely abrogates biosynthetic capacity (Ercan-Sencicek et al., 2010). Finally, the hypothesized ability of HA to modulate DA levels in the CNS (Haas et al., 2008) leads to a testable hypothesis: that reduced HA production produces TS phenomenology through dysregulation of dopaminergic modulation of the basal ganglia.

## RESULTS

### Individuals carrying a hypomorphic *Hdc* allele exhibit tics; *Hdc* knockout mice, and heterozygotes, exhibit potentiated tic-like stereotypies

The clinical histories of the carriers of the *Hdc*W317X mutation have been described (Ercan-Sencicek et al., 2010). Diagnoses were confirmed using the Structured Clinical Interview for DSM-IV (First et al., 1997) (Table S1). Tics were within a typical range of severity. There was no significant correlation between age and tic severity, as measured by the Yale Global Tic Severity Scale (Leckman et al., 1989;  $p > 0.4$ ). Four of the nine had comorbid OCD symptoms; three had a history of depressive symptoms; one had high-functioning autism. None were treated with high-potency D2 antagonists such as haloperidol (Bloch, 2008). Three were on SSRI antidepressants for treatment of comorbid depressive, anxiety, and OCD symptoms.

We turned to a mouse model to establish the causal relationship of *Hdc* disruption to key behavioral and neurochemical characteristics of TS. *Hdc* W317X produces a truncated protein without enzymatic activity (Ercan-Sencicek et al., 2010; see Figure 1A). *Hdc* knockout mice produce no HDC protein (Krusong et al., 2011; Ohtsu et al., 2001). [HA] was reduced in +/- mice, confirming haploinsufficiency, and was undetectable in -/- animals (Figure 1B).

Psychostimulants can potentiate tics and tic-like stereotypies. We assessed motor stereotypies before and after administration of a single dose of intraperitoneal (IP) D-amphetamine (8.5 mg/kg in sterile saline, the threshold for production of observable motor stereotypies in wild-type animals on this genetic background).

*Hdc* +/- and -/- mice showed normal baseline locomotion (Figure 1C), exploratory rearing, and center occupancy in an open field (Figure 1D), and no evident spontaneous motor stereotypies. Wild-type mice showed locomotor activation after amphetamine, which was attenuated in *Hdc* +/- and -/- mice (Figure 1C). Reduced locomotion is often seen in wild-type mice administered high doses of amphetamine, as stereotypical movements compete with it. We observationally quantified a range of stereotypies after D-amphetamine (Kelley, 2001); the majority consisted of repetitive focused sniffing and orofacial movements (see Supplementary Video 1-3). Knockout mice showed markedly increased motor stereotypies (Figure 1E).

The reduced locomotion in heterozygotes suggests they were engaged in stereotypies that competed with locomotor behavior but fell below the threshold of detection. We administered a higher dose of D-amphetamine (10 mg/kg), in an independent cohort of mice, to see whether enhanced stereotypies would manifest in heterozygotes. Locomotor activation was again attenuated in +/- and -/- mice (Figure S1E). At this higher dose, many of the knockouts became immobile, rendering quantification of stereotypy impossible. Heterozygotes now showed increased stereotypy (Figure 1F). Thus, *Hdc* deficiency potentiates tic-like stereotypies.

### Stereotypies in *Hdc* KO mice are mitigated by haloperidol pretreatment

We tested the responsiveness of tic-like stereotypies to haloperidol, a dopamine D2 receptor antagonist, in an independent cohort of *Hdc* mice (Figure 2A). HA levels go up during the active circadian phase (Haas, 2008; see below, Figure 5B, S5B). Thus, behavioral phenotypes may vary across the light-dark cycle. We performed these experiments at night, to replicate the core phenotype while HA levels are elevated in wild-type animals (because mice are nocturnal).

Haloperidol pretreatment produced a modest but statistically significant reduction in locomotor activity after amphetamine that did not differ across genotypes (Figure 2B, S2). *Hdc*  $-/-$  mice pretreated with IP saline again exhibited tic-like stereotypies after 8.5 mg/kg D-amphetamine; heterozygotes also showed elevated stereotypies (Figure 2C). This experiment was done in older animals (7-9 months) than the previously (Figure 1E, F; 3-7 months), suggesting that stereotypy does not vary with age; this recapitulates the persistence of tics seen in adult carriers of the *Hdc* W317X mutation (Table S1).

Pretreatment with 0.3 mg/kg haloperidol attenuated stereotypies in  $-/-$  mice and eliminated them in heterozygotes (Figure 2D, F). Pretreatment with 0.6 mg/kg haloperidol eliminated stereotypies in all genotypes (Figure 2E, F). The haloperidol effect was significant in the *Hdc*  $-/-$  mice, considered in isolation (RM-ANOVA: haloperidol dose  $\times$  time interaction,  $F[10,40] = 2.19$ ,  $p = 0.039$ ), but not in the other genotypes. Collapsing across post-amphetamine time-points, there was a main effect of genotype in the saline-treated condition (Figure 2F; ANOVA of genotype and treatment order,  $F[2,10] = 5.70$ ,  $p = 0.022$ ) that was attenuated at the 0.3 mg/kg ( $F[2,9] = 2.09$ ,  $p = 0.18$ ) and 0.6 mg/kg doses of haloperidol ( $F[2,9] = 0.86$ ,  $p > 0.4$ ). All animals received the highest haloperidol dose on the third day; key effects remained significant when analysis was restricted to only saline and 0.3 mg/kg haloperidol, with treatment order randomized and the investigator blind to treatment: RM-ANOVA with treatment order as an independent factor (main effect of haloperidol,  $F[1,55] = 6.99$ ,  $p = 0.023$ ; main effect of genotype,  $F[2,11] = 3.99$ ,  $p = 0.05$ ; main effect of time,  $F[5,55] = 6.46$ ,  $p < 0.001$ ; time  $\times$  genotype interaction,  $F[10,55] = 2.69$ ,  $p = 0.009$ ).

To better quantify the potentiated stereotypies in *Hdc*  $+/-$  and  $-/-$  mice, we combined data from the three experiments described above (Figure 1E, 1F, 2C). In the combined dataset ( $n = 17 +/+$ ,  $17 +/-$ ,  $11 -/-$ ), the differential induction of stereotypies across genotypes was highly significant (RM-ANOVA with genotype and experiment as between-subject factors: main effect of genotype,  $F[2,35] = 10.8$ ,  $p < 0.001$ ; main effect of time,  $F[5,175] = 26.8$ ,  $p < 0.001$ ; time  $\times$  genotype interaction,  $F[10,175] = 3.6$ ,  $p < 0.001$ ). Bonferroni-corrected post-hoc comparisons showed that  $-/-$  mice have more stereotypies than  $+/+$  ( $p < 0.001$ ) and  $+/-$  ( $p = 0.004$ );  $+/-$  mice had nominally more stereotypies than  $+/+$ , but this difference did not reach significance.

### Stereotypy in *Hdc* knockout mice is mitigated by HA repletion

If the potentiation of tic-like stereotypies is a direct consequence of HA reduction, then it should be mitigated by direct repletion of brain histamine. We infused HA or saline intracerebroventricularly (ICV) immediately before administering amphetamine in *Hdc*  $+/+$  and  $-/-$  mice. Stereotypy was delayed and reduced in amplitude in surgically cannulated animals, necessitating a modified monitoring paradigm (see Methods). All animals received both saline and HA pretreatment in counterbalanced order.

When ICV saline was given immediately before amphetamine, we again observed focused sniffing stereotypies (figure 1E, F; Figure 2C, F) in both  $+/+$  and  $-/-$  animals. As in previous experiments, they were elevated in *Hdc*  $-/-$  animals (Figure 3A).

HA pretreatment almost completely eliminated these focused stereotypies, in both genotypes (figure 3A, B). Because of a lack of variance in measured stereotypies in the HA-pretreated animals, analysis of HA effects was performed using nonparametric ANOVA-like statistics (see Methods). There was a robust effect of HA pretreatment ( $df = 1$ ,  $ATS = 28.47$ ,  $p < 0.0001$ ) and of time ( $df = 1$ ,  $ATS = 8.03$ ,  $p < 0.0001$ ) and a  $HA \times$  time interaction ( $df = 2.8$ ,  $ATS = 6.69$ ,  $p = 0.0002$ ). Collapsing across post-amphetamine time points, stereotypies were dramatically reduced by HA pretreatment in both genotypes (Mann-Whitney U test:  $p < 0.05$  for *Hdc*  $+/+$  mice,  $p < 0.001$  for *Hdc*  $-/-$  mice).

Direct delivery of HA into the brain is sedating (Kalivas, 1982; Kamei et al., 1983; Onodera and Ogura, 1981). Consistent with this, HA-pretreated mice showed reduced locomotor activity, (Figure S3B), especially initially; HA-treated *Hdc*  $-/-$  showed greater locomotor activation in the second half of the hour than HA-treated  $+/+$  mice, permitting dissociation of effects on locomotion and stereotypy. In the first 30 minutes following HA (Figure 3C, left panel) there was a significant effect of HA (ANOVA:  $F[1,38] = 25.9$ ,  $p < 0.001$ ) with a trend-level genotype  $\times$  HA interaction ( $F[1,25] = 2.96$ ,  $p = 0.093$ ) and post-hoc differences between the HA-treated and saline-treated groups. In the latter 30 minutes, the effect of HA was at trend level ( $F[1,38] = 2.90$ ,  $p = 0.097$ ) and the genotype  $\times$  HA interaction was significant ( $F[1,38] = 5.2$ ,  $p = 0.028$ ), with only the HA-treated  $+/+$  animals showing significantly reduced activity (Figure 3C). Since the reductions in stereotypy seen in HA-pretreated *Hdc*  $-/-$  mice are apparent during the latter half of the first hour following amphetamine administration (Figure 3A), this rules out the possibility that the reduction is due simply to sedation. Non-stereotypic, exploratory sniffing was not altered by HA pretreatment (see Figure S3C, D).

Excessive grooming has been proposed to be a behavioral manifestation of OCD-like pathology (Shmelkov et al., 2010; Welch et al., 2007). Surprisingly, HA infusion increased grooming in both genotypes (Figure S3E, F). Stereotypies and abnormal grooming may represent distinct perturbations of the basal ganglia circuitry.

### **Sensorimotor gating deficits in humans and mice carrying a mutant *Hdc* gene**

—TS is characterized by deficits in sensorimotor gating, reflected in a deficit in prepulse inhibition of startle (PPI) (Baldan Ramsey et al., 2011; Castellanos et al., 1996; Swerdlow et al., 2001; Terrados et al., 2012). PPI can be measured in humans and experimental animals using nearly identical protocols (Baldan Ramsey et al., 2011; Swerdlow, 2012). PPI deficits are also seen in other neuropsychiatric conditions, including OCD (Ahmari et al., 2012; de Leeuw et al., 2010; Hoenig et al., 2005) and schizophrenia (Braff et al., 1978; Turetsky et al., 2007). However, in the context of a genetic abnormality independently associated with TS, an endophenotype such as a PPI deficit can provide valuable reinforcing face validity.

We tested PPI in patients carrying the *Hdc* W317X mutation. PPI of the startle response to an auditory stimulus, monitored by electromyogram of the orbicularis oculi muscle, was assessed in the nine individuals carrying the *Hdc* W317X mutation and in nine age- and sex-matched controls, using standard procedures (Lipschitz et al., 2005). TS patients had reduced auditory PPI, measured either 15 or 20 msec after the onset of the startle stimulus (Figure 4A, S4A). There was no between-group difference in startle amplitude on trials in which no prepulse was presented ( $t[16] = 0.82$ ;  $p = 0.43$  at 20 msec). PPI within the TS group was variable (Figure S4A). There was a weak negative association between PPI and age among the patients that did not reach statistical significance (Figure 4B). Heterogeneity of PPI in the patient group was not explained by gender, medication status, comorbidity, or other clinical variables (Figure S4B-G). These data represent the first time, to our knowledge, that a PPI deficit has been associated with a specific genetic abnormality in humans (Kohl et al., 2013).

We predicted that *Hdc* knockout mice would recapitulate this endophenotype. We tested auditory PPI in mice, following a standard protocol (Baldan Ramsey et al., 2011). *Hdc* +/- and -/- mice exhibited a significant PPI deficit (Figure 4C, S4H).

There was a trend towards higher baseline startle in +/- and -/- mice than in +/+ controls (Figure S4I), and PPI correlated negatively with baseline startle across all animals (Figure 4D). However, statistical significance was increased, not attenuated, when startle was included as a covariate, controlling for the possibility that a genotype effect on startle intensity underlies the PPI phenotype (Figure 4D, S4J). We found no statistically significant effect of animals' age on the PPI phenotype; there was a nominal association of age with an increased PPI phenotype in the knockout mice, though it did not approach statistical significance (Figure 4E). We repeated this experiment at night, with similar results (Figure 4F, S4O,P). *Hdc* -/- mice have been reported to display increased anxiety (e.g. Dere et al., 2004), which may affect startle; however, we found no evidence of altered anxiety in the elevated plus maze of the open field in these animals, possibly because they are on a different genetic background than those described previously (Figure 1D, S1A-D).

### **Striatal dopamine is negatively regulated by histamine and is dysregulated in *Hdc* knockout mice**

HA has been hypothesized to negatively regulate DA (Haas et al., 2008; Schlicker et al., 1994). To examine this *in vivo*, we infused HA ICV into wild-type mice and measured striatal DA using microdialysis. ICV HA (20 µg in sterile saline) led to a marked reduction in DA in the contralateral striatum (Figure 5A), accompanied by reduced activity (data not shown). In contrast, saline infusion had no lasting effect on striatal HA levels.

*Hdc* knockout mice have increased striatal DA turnover (Dere et al., 2003). We assayed striatal [HA] and [DA] using *in vivo* microdialysis (Figure S5A, B, D). HA levels were dramatically reduced in -/- mice (Figure 5B). In +/+ animals, [HA] increased during the dark (active) phase (Figure S5E), reflecting its role in arousal (Haas et al., 2008).

There was not a main effect of genotype on unnormalized daytime striatal [DA] levels in knockout mice, although given the variability inherent in unnormalized microdialysis data, we cannot rule out a subtle abnormality. However, there was a significant genotype by time interaction, with increased [DA] in *Hdc* -/- mice in the dark phase, when HA is high in +/+ mice (Figure 5C). We isolated this effect by normalizing DA to the daytime baseline, thereby reducing between-subject technical variability (see Figure S5E, F); analysis of normalized data confirmed a significantly higher DA in *Hdc* -/- mice during the dark cycle (Figure 5D).

**Dopamine signaling is enhanced and striasomal activation is potentiated in *Hdc* -/- mice**—We examined *Fos* immunoreactivity as a surrogate marker for neuronal activation in striatal medium spiny neurons (Figure 6A, B). *Fos* is upregulated in D1-expressing medium spiny neurons (MSNs) in response to pharmacological elevations in DA (Young et al., 1991). Doses of psychostimulants that produce stereotypy preferentially upregulate *Fos* in MSNs in striatal compartments known as striasomes (Canales and Graybiel, 2000); an imbalance between activation of striasomal and matrix MSNs may lead to stereotypies and tics (Canales and Graybiel, 2000; Crittenden and Graybiel, 2011).

At baseline, *Fos* was modestly elevated in both striasomes and matrix of *Hdc* - mice, relative to +/+ sibling controls (Figure 6C). As this tissue was collected during the day, this suggests DA dysregulation in *Hdc* -/- mice even in the inactive phase. There was nominally higher *Fos* in the matrix than in the striasomes across genotypes, but this did not reach statistical significance ( $F[1,10] = 0.8$ ,  $p = 0.4$ ).

Forty-five minutes after amphetamine injection (5 mg/kg D-amphetamine, to avoid saturating the response) there was a marked increase in *Fos* expression in both genotypes and in both compartments. *Fos* was greatly increased in striasomes of *Hdc*  $-/-$  mice, relative both to matrix in the same animals and to striasomes in controls (Figure 6D). The genotype effect was restricted to the striasomal compartment; the striasome-matrix difference was thus markedly enhanced in *Hdc*  $-/-$  mice.

**Dysregulated D2+D3 receptors in the basal ganglia of TS patients carrying the *Hdc* W317X mutation**—DA cannot be directly assayed *in vivo* in humans. However, dysregulation of dopaminergic modulation within the basal ganglia may be reflected in compensatory changes in DA receptors. DA receptors can be examined *in vivo* in patients using positron emission tomography (PET).

We focused on D2 and D3 dopamine receptors, because D2 antagonists have therapeutic efficacy in TS (Bloch, 2008) and because these receptors exhibit homeostatic change upon chronic hyperstimulation. D3 receptors on midbrain dopaminergic neurons may function as inhibitory autoreceptors (Stanwood et al., 2000a; White and Wang, 1984); substantia nigra D2/D3 binding is increased after chronic stimulation in rats (Stanwood et al., 2000b) and in chronic users of cocaine (Payer et al., 2013). Striatal D2 receptors are downregulated after chronic pharmacological stimulation in rats and humans (Stanwood et al., 2000b; Volkow et al., 2009) and in hyperdopaminergic mice (Fauchey et al., 2000).

PET ligand binding permits only limited discrimination between D2 and D3 receptors. We used  $^{11}\text{C}$ -PHNO, an agonist tracer that binds to high-affinity D2 and D3 receptors, with preference for D3. This allows imaging of both the dorsal striatum, where D2 receptor density is very high, and the substantia nigra, where D3 receptors predominate (Graff-Guerrero et al., 2008; Narendran et al., 2006; Rabiner et al., 2009; Tziortzi et al., 2011).

PET scanning was performed in the 4 adult patients; usable data were acquired in 3 and compared to data from 9 controls matched for age, sex, and body mass index (Figure 7A, B; Table S2, S3). Plasma free fraction and nonspecific PHNO binding did not differ between groups (Figure S6A-C). There was a significant increase in PHNO binding in patients in the globus pallidus (GP) and substantia nigra (SN; Figure 7C). This difference did not survive correction for multiple comparisons in the GP ( $t[10] = 2.29$ ; uncorrected  $p = 0.045$ ) but did in the substantia nigra ( $t[10] = 3.27$ , uncorrected  $p = 0.008$ ; see also Figure 7D).

**D2+D3 receptor dysregulation in *Hdc* KO and heterozygous mice**—We examined D2+D3 receptor density in *Hdc*  $+/-$  and  $-/-$  mice using  $^3\text{H}$ -raclopride binding to brain slices *ex vivo*, where there is no ambient DA. Raclopride binding was seen in SN (Figure 8A; Figure S6D) and striatum (Figure 8D; Figure S6E). In the substantia nigra, higher  $^3\text{H}$ -raclopride binding was found in knockouts and heterozygotes than in wild-type controls (Figure 8B, C). SN raclopride binding correlated with the number of knockout alleles. This parallel to the human PET data establishes that this receptor change is causally attributable to *Hdc* genotype and strongly suggests that the abnormality seen *in vivo* in patients reflects increased receptor density or affinity, rather than reduced [DA] in these structures.

Raclopride binding in the dorsal striatum showed a small but statistically significant reduction as a function of genotype (4-14% reduction in  $+/-$  and  $-/-$  mice; Figure 8D, E). Regression analysis across genotypes and caudal-rostral location showed a significant inverse relationship between dorsal striatal raclopride binding and number of HDC knockout alleles (Figure 8E; see Figure S6E), suggesting D2 downregulation in the dorsal striatum in HDC knockout mice. This reduction was not seen in the human PET data. This discrepancy

may represent a species difference. Alternatively, our power to detect such a small difference may be limited due to the small number of subjects carrying the *Hdc* W317X mutation we were able to image.

This reduction in striatal D2+D3 binding and the increased substantia nigra D2+D3 binding (Figure 7D, 8C,E) may represent cellular responses to chronic elevation of striatal DA (Stanwood et al., 2000b). Consistent with this possibility, there was an inverse relationship between striatal (measured at caudal-rostral levels 5 and 6, where the genotype effect was most prominent; see Figure 8E, S6E) and nigral raclopride binding (Figure 8F).

## DISCUSSION

Tourette syndrome is a developmental neuropsychiatric disorder that is associated with basal ganglia abnormalities (Willams et al., 2013). Recent genetic findings have suggested, for the first time, that dysregulation of histaminergic neurotransmission represent a rare cause of TS (Bloch et al., 2011; Ercan-Sencicek et al., 2010; Fernandez et al., 2012). We have used parallel analysis in *Hdc* knockout mice and in nine unique patients known to carry the hypomorphic *Hdc* W317X allele to confirm this association.

### ***Hdc* disruption causes core behavioral and neurochemical features of TS**

The genetic relationship between the *Hdc* W317X mutation and TS in the index family is statistically compelling (Ercan-Sencicek et al., 2010). Direct evidence for causality, however, is not achievable with human genetic studies alone.

We find parallel TS-associated behavioral and neurochemical abnormalities in patients carrying the *Hdc* W317X mutation and *Hdc* knockout and heterozygous mice (Table 1). This provides strong evidence for the causal association between *Hdc* disruption and Tourette syndrome.

### **Histamine regulates dopaminergic modulation of the basal ganglia circuitry**

It has been speculated that histamine regulates DA in the basal ganglia *in vivo* (Haas et al., 2008; Schlicker et al., 1994). *Hdc* knockout mice were reported to exhibit increased DA turnover (Dere et al., 2003); indirect pharmacological enhancement of central HA modulates DA-associated stereotypical behaviors (Joshi et al., 1981; Kitanaka et al., 2010; Paul et al., 2000). We find that exogenously administered HA profoundly reduces striatal DA levels (Figure 5A). In knockout mice we do not observe a clear change in baseline DA during the day, but find a dysregulation that emerges during the animals' active phase, when HA levels in wild-type animals are highest (Figure 5B-D).

The direct measure of DA (Figure 5) and the alterations in baseline *Fos* (Figure 6) suggest chronic, if mild and fluctuating, elevation of DA. The pattern of receptor alterations observed in the *Hdc* knockout mice is consistent with the pattern expected after chronic dopaminergic hyperstimulation. This pattern is partially recapitulated in patients carrying the *Hdc* W317X mutation, in whom we find elevated binding by the D2+D3 agonist radiotracer <sup>11</sup>C-PHNO in the substantia nigra and, less profoundly, in the globus pallidus.

These data represent the first *in vivo* evidence in humans of a direct relationship between alterations in histaminergic neurotransmission and dopaminergic modulation of the basal ganglia circuitry.



## Histaminergic regulation of information processing in the basal ganglia

Despite the prominent expression of HA receptors in the basal ganglia, the functional effects of HA in this circuitry have not been extensively studied. Histaminergic axons in the striatum are relatively sparse and make few direct synaptic contacts, (Takagi et al., 1986); however, the axons are varicose (Takagi et al., 1986), and the wild-type striatum contains a high amount of HDC protein (Krusong et al., 2011). Several striatal synapses are regulated by HA *in vitro* (Ellender et al., 2011). The ability of HA to reduce striatal DA levels (Figure 5A) suggests that it may provide a brake on DA.

The circadian modulation of HA (Figure 5B) suggests that it may produce a circadian modulation of striatal information processing, although direct evidence for this speculation is lacking. This circadian modulation of HA may have important implications for pathophysiology. Tics in Tourette syndrome typically do not occur during sleep. If the emergence (or amplification) of an abnormality in DA that we observe in these mice (Figure 5C,D) is a general phenomenon, it may help explain this observation in TS and other movement disorder

Dysregulation of dopaminergic modulation in the basal ganglia is unlikely to be the only relevant effect of reduced histaminergic tone. Hypothalamic HDC-expressing neurons project widely throughout the CNS. Indeed, other investigations in the *Hdc* knockout mice indicate abnormalities in hippocampal and cortical function (e.g. Acevedo et al., 2006; Dere et al., 2004). The inhibitory H3 receptor is expressed presynaptically on dopaminergic terminals and may explain the ability of HA to reduce striatal DA, but it is also expressed presynaptically on other cell types and regulates other neurotransmitters (Ellender et al., 2011; Haas et al., 2008; Schlicker et al., 1994). Histamine H1 and H2 receptors are also expressed prominently in the basal ganglia circuitry, and throughout the brain (Haas et al., 2008; Traiffort et al., 1994; Traiffort et al., 1995; Zhou et al., 2006). How alterations in information processing beyond the basal ganglia contribute to pathophysiological changes relevant to TS is an important area for future study.

## *Hdc* knockout mice as a pathophysiologically realistic model of Tourette syndrome

*Hdc* abnormalities are unlikely to explain more than a small fraction of TS cases. However, modeling this rare cause of TS in an animal may provide an entree into more generalizable pathophysiological disruptions.

Animal models have traditionally been evaluated on the basis of face validity (their recapitulation of recognizable signs and symptoms of the modeled disease), predictive validity (their ability to predict what drugs will be efficacious in disease), and construct validity (their recapitulation of hypothesized core pathophysiology). The first two are problematic in the case of neuropsychiatric disease (Nestler and Hyman, 2010; Pittenger, 2011). Face validity raises challenges because of the subtle and subjective nature of psychiatric symptomatology. Not all repetitive behaviors are tics. Clinically, tics are characterized by premonitory urges, the fact that they can often be resisted at least to a limited extent, and the way that tic emission discharges a sense of discomfort. None of these can be readily evaluated in a mouse model. Predictive validity also must contend with a lack of specificity. D2 antagonists, for example, are used in the treatment of TS, but also for psychosis, bipolar disorder, depression, OCD, delirium, and other conditions. They are not efficacious in every case. In this context, response to a medication does not uniquely validate an animal model, and a lack of response does not invalidate it. Construct validity is critical to the elaboration of a pathophysiologically informative model.

The *Hdc* knockout mice represent the first model of TS to derive construct validity from a high-penetrance disease-associated allele. Behavioral phenotypes endow the model with reinforcing face validity (Figure 1-4). Enhanced stereotypy and reduced PPI are not specific to TS, but in the context of the inherent construct validity of the *Hdc* knockout mouse, they confirm that relevant processes have been disrupted. Similarly, the mitigation of tic-like stereotypies by haloperidol (Figure 2) is not a TS-specific result, but this predictive validity further reinforces the *Hdc* knockout mouse as a faithful recapitulation of core aspects of the pathophysiology of disease.

Patients carrying the *Hdc* W317X are not likely to be wholly deficient in brain HA; their wild-type allele should permit some production. Therefore, it may be that *Hdc* +/- mice more faithfully recapitulate the disease state than full knockouts. Given this, it is important that *Hdc* +/- mice show a phenotype intermediate between wild-type and full knockout mice in all key experiments: the potentiation of tic-like stereotypy (Figure 1D, 1E, 2B, 2D), the impairment in prepulse inhibition (Figure 4B), and the dysregulation of D2+D3 receptors in the basal ganglia (Figure 8C, E).

### Clinical implications

Excessive movements can be produced by increased activity of the striatonigral (direct) pathway or reduced activity of the striatopallidal (indirect) pathway. Tics may derive from hypoactivity of the indirect pathway, leading to deficient inhibition of off-target movements (Albin, 2006; Mink, 2001; Willams et al., 2013). Chronic moderate increases in DA in *Hdc* knockout animals might produce such a state. The D2 receptor expressed by MSNs of the indirect pathway has a higher affinity for DA than D1 receptor (Rankin et al., 2010) and may be more responsive to modest, chronic elevations in DA. Tonically increased D2 tone would lead to tonically reduced activity in MSNs of the indirect pathway (Mink, 2001); this would be mitigated by D2 blockade, as in Figure 2.

We find that HA repletion mitigates potentiated stereotypies in these animals (Figure 3). A similar effect was suggested by indirect pharmacological modulation of HA levels in wild-type mice (Joshi et al., 1981; Kitanaka et al., 2007; Paul et al., 2000). This suggests that increasing brain HA may be of therapeutic value in TS. Dietary supplementation with histidine might increase HA production (Kitanaka et al., 2010). H3 receptor antagonists may increase HA release by blocking inhibitory autoreceptors on histaminergic terminals (Flik et al., 2011), although their effect on other cells is a complication (Ellender et al., 2011; Schlicker et al., 1994). The generation of such testable hypotheses illustrates the potential utility of this pathophysiologically valid animal model.

## METHODS

More detailed Methods are given in the Supplementary Material.

### Mice

Generation of *Hdc* knockout mice has been described previously (Ohtsu et al., 2001). Adult male mice, aged 3-9 months, were used in all experiments.

### HDC activity assay and histamine quantification

The W317X mutation was introduced into the mouse *Hdc* gene using standard molecular cloning techniques. HDC enzymatic activity (Figure 1A) was quantified as previously described (Ercan-Sencicek et al., 2010). Quantification of tissue [HA] (Figure 1B) was performed as described previously (Krusong et al., 2011). Quantification of microdialysate [HA] (Figure 5B), which is two orders of magnitude lower, was by mass spectrometry.

## Open field exploration and stereotypy in mice

Adult male mice were placed in an unfamiliar novel open-topped white opaque plexiglass box and their exploratory activity was monitored for 20 minutes using both observation and a video tracking system (AnyMaze). After 20 minutes, D-amphetamine (Sigma, St. Louis; 8.5 mg/kg or 10 mg/kg) or saline was administered intraperitoneally and monitoring was continued for another 30 minutes. A broad range of stereotypical behaviors were noted (Kelley, 2001); the vast majority of observed stereotypies consisted of repetitive focused sniffing movements, which are reported (See Supplementary Videos 1-3). For haloperidol pretreatment (Figure 2), animals were monitored in the environment for 20 minutes, then injected IP with haloperidol (Sigma, St. Louis, 0.3 or 0.6 mg/kg) and observed for a further 15 minutes, and then injected with amphetamine or saline as above (Figure 2A). All animals in this experiment (Figure 2) received both haloperidol and saline, in counterbalanced order, 5-7 days apart; treatment order was included as an independent factor of no interest in the ANOVA analysis.

## Elevated plus maze in mice

Elevated plus maze analysis was performed as described previously (Lee et al., 2008).

## Histamine mitigation of stereotypy

Pilot experiments showed surgical cannulation to reduce and delay amphetamine-induced stereotypies; to increase sensitivity, we extended our observation period and observed animals in higher ambient light in a clear-sided enclosure (a standard rat housing cage) rather than a larger opaque-sided open-field box. ICV cannulae were implanted using standard stereotaxic surgical technique; animals were allowed to recover for at least 5 days following surgery before behavioral testing. Locomotor activity was measured before and after administration by infrared beam-breaks on an open-field apparatus (Med Associates, Burlington, VT). Mice were habituated to the environment for 60 minutes before the first amphetamine treatment (Supplementary Figure 3A). They were then briefly immobilized and treated ICV with HA (20  $\mu$ g in 1  $\mu$ l sterile saline; (Kalivas, 1982; Kamei et al., 1983, 1984; Onodera and Ogura, 1981)) or saline and then immediately injected IP with amphetamine (8.5 mg/kg). Stereotypical behaviors were measured at intervals over 90 minutes by a trained observer blind to animal genotype and drug treatment. The procedure was repeated 5-7 days later with the other treatment (saline vs. HA), in counterbalanced order.

Because of the longer observation period, quantification of stereotypy was performed by instantaneous sampling rather than continuous monitoring, using a well-validated method (Fray et al., 1980); the dependent measure is the total number of sampled 10-second intervals during which a behavior was present.

## Startle and prepulse inhibition of startle

Startle to a broad-band acoustic stimulus was measured using standard procedures as described previously (Baldan Ramsey et al., 2011). The initial PPI experiment (Figure 4C, S4H-N) was performed using a 100 msec prepulse-pulse interval; replication in the dark phase (Figure 4F, S4O,P) was performed using a 200 msec interval, which was found in pilot experiments (not shown) to produce a more robust separation of genotypes.

## *In vivo* microdialysis

Adult male mice were implanted unilaterally with a guide cannula targeted to the dorsal striatum using standard stereotaxic technique; animals for HA infusion (Figure 5A) were simultaneously implanted contralaterally with an ICV cannula guide. After habituation,

microdialysate was collected in 30 min samples and DA levels were measured using standard techniques (Tellez et al., 2013). Following microdialysis, mice were euthanized and their brains examined to establish cannula placement. Animals in which chromatograms suggested excessive bleeding or anatomical analysis indicated cannula misplacement were excluded, prior to data analysis.

### Histamine infusion with microdialysis

After recovery from surgery, a microdialysis cannula was inserted. Microdialysis was performed as above, with the exception that microdialysate was perfused at 2  $\mu$ l/min and collected in 10-min aliquots. Following a 3-hour baseline, mice were briefly immobilized and HA (20  $\mu$ g in 1  $\mu$ l sterile saline) or an equivalent amount of saline was infused over 2 minutes; mice were then monitored for 90 more minutes. DA was measured subsequently using HPLC, as above. All mice received both HA and saline, separated by 1 week, in counterbalanced order.

### Fos immunoreactivity

45 minutes following saline or D-amphetamine (5 mg/kg IP in sterile saline) administration, brains were removed, fixed overnight in 4% paraformaldehyde, and stored in 30% sucrose. 30  $\mu$ m floating sections were immunostained following standard procedures (see Supplementary Methods for details) with goat anti *c-fos* (1:500, Santa Cruz Biotechnology) and rabbit anti  $\mu$ -opioid receptor (1:1000, Immunostar) antibodies followed by Alexafluor-coupled secondary antibodies (Jackson Immnoresearch). Fluorescence was visualized on a confocal microscope. *Fos*-positive cells were counted in  $\mu$ -positive (striae) and  $\mu$ -negative (matrix) compartments bilaterally in multiple slices per animal (Young et al., 1991).

### Raclopride binding in mice

$^3$ H-raclopride binding to unfixed fresh-frozen slices of mouse brain was determined as described previously (Fasano et al., 2009). Signal was visualized using a phosphor imager system (Cyclone Plus, Perkin Elmer, Waltham, MA). Images were analyzed using Photoshop (Adobe, San Jose, CA), as further described in the Supplementary Methods and in Figures S6.

### Human subjects

9 individuals from a single family who have previously been identified as having a current or past diagnosis of a tic disorder and as carrying the *Hdc* W317X mutation (Ercan-Sencicek et al., 2010) were evaluated for this study. Controls, matched for age and sex and (for PET imaging) for body mass index were recruited from the community through advertising. Patients and controls were assessed using standard clinical instruments to confirm diagnoses and quantify symptomatology.

### Prepulse inhibition in patients

Auditory startle and PPI were assessed as previously described (Lipschitz et al., 2005) using the SR-HLAB system (San Diego Instruments, San Diego, CA, USA).

### Positron emission tomography imaging

[ $^{11}$ C]-(+)-PHNO was prepared and PET imaging performed as described previously (Narendran et al., 2006; Tziortzi et al., 2011); see Supplementary Table 3. Dynamic scan data were constructed with all corrections using the MOLAR algorithm (Carson et al., 2003). Arterial blood samples were collected throughout scanning to measure the arterial

input function. [ $^{11}\text{C}$ ]-(+)-PHNO volumes of distribution ( $V_T$ ) were quantified using the multilinear analysis MA1 (Ichise et al., 2002) using arterial input function data.

### Statistical analysis

All analysis was performed using PASW Statistics 18.0 (SPSS/IBM, Armonk, NY) in consultation with a biostatistician. T-tests, correlations, and ANOVA, with repeated measures and/or covariance as appropriate, were employed as described in the text and figure legends for each dataset. 2-tailed tests with  $\alpha=0.05$  were used expect where clear, directional *a priori* hypotheses justified an alpha of 0.1, as indicated.

In the analysis of focused sniffing stereotypy following ICV histamine (Figure 3), parametric statistics were not appropriate because of the very low variance in the HA-treated groups (no stereotypy was seen at most time points), and non-parametric ANOVA-like statistics were used. The key PET finding of increased PHNO binding in the substantia nigra was confirmed using the nonparametric Mann-Whitney U test (Figure 5D) because of the low n in the TS group.

### Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

### Acknowledgments

We thank Stacey Wilber for assistance with mouse genotyping, Theresa Brand for assistance with histamine analysis in tissue, the staff of the Yale PET Center for support in all PET studies and analyses, Brian Pittman for statistical consultation and support, and Marina Picciotto, Ronald Duman, and Ralph DiLeone for helpful discussion and comments on the manuscript. This work was supported by The Allison Family Foundation (CP), NIH grants K08MH081190 (CP), R01MH091861 (CP), PL1DA024860 (GMA), R01NS056276 (MWS), T32MH014276 (LCB; PI: Duman), T32MH018268 (KW; PI: Leckman), UL1RR024139 (Yale Center for Clinical Investigation Pilot Award to CP; PI: Sherwin), 2P50AA012870 (JHK), and D43TW06166 (KK; PI: Gelertner and Malison). Additional support came from the Tourette Syndrome Association (CP, LCB), the Yale Program on Neurogenetics (GES, MWS), the Yale PET Center (YSD, JDG), the Brain Research Foundation, Chicago, IL, the Overlook International Fund, Pfizer Global Research (RG and ZAH), and the State of Connecticut through its support of the Ribicoff Research Facilities at the Connecticut Mental Health Center (CP, LCB, VP, MR).

### REFERENCES

- Acevedo SF, Ohtsu H, Benice TS, Rizk-Jackson A, Raber J. Age-dependent measures of anxiety and cognition in male histidine decarboxylase knockout (Hdc $^{-/-}$ ) mice. *Brain Res.* 2006; 1071:113–123. [PubMed: 16412995]
- Ahmari SE, Risbrough VB, Geyer MA, Simpson HB. Impaired sensorimotor gating in unmedicated adults with obsessive-compulsive disorder. *Neuropsychopharmacology.* 2012; 37:1216–1223. [PubMed: 22218093]
- Albin RL. Neurobiology of basal ganglia and Tourette syndrome: striatal and dopamine function. *Advances in neurology.* 2006; 99:99–106. [PubMed: 16536355]
- Albin RL, Young AB, Penney JB. The functional anatomy of basal ganglia disorders. *Trends in neurosciences.* 1989; 12:366–375. [PubMed: 2479133]
- Alexander GE, DeLong MR, Strick PL. Parallel organization of functionally segregated circuits linking basal ganglia and cortex. *Annual review of neuroscience.* 1986; 9:357–381.
- Baldan Ramsey LC, Xu M, Wood N, Pittenger C. Lesions of the dorsomedial striatum disrupt prepulse inhibition. *Neuroscience.* 2011; 180:222–228. [PubMed: 21315809]
- Bloch M, State M, Pittenger C. Recent advances in Tourette syndrome. *Curr Opin Neurol.* 2011; 24:119–125. [PubMed: 21386676]
- Bloch MH. Emerging treatments for Tourette's disorder. *Curr Psychiatry Rep.* 2008; 10:323–330. [PubMed: 18627671]


- Braff D, Stone C, Callaway E, Geyer M, Glick I, Bali L. Prestimulus effects on human startle reflex in normals and schizophrenics. *Psychophysiology*. 1978; 15:339–343. [PubMed: 693742]
- Canales JJ, Graybiel AM. A measure of striatal function predicts motor stereotypy. *Nat Neurosci*. 2000; 3:377–383. [PubMed: 10725928]
- Carson RE, Barker W, Liow J-S, Johnson C. Design of a motion- compensation OSEM list-mode algorithm for resolution-recovery reconstruction for the HRRT. *Nuclear Science Symposium Conference Record, 2003 IEEE*. 2003; 5:3281–3285.
- Castellanos FX, Fine EJ, Kaysen D, Marsh WL, Rapoport JL, Hallett M. Sensorimotor gating in boys with Tourette's syndrome and ADHD: preliminary results. *Biological psychiatry*. 1996; 39:33–41. [PubMed: 8719124]
- Choi EY, Yeo BT, Buckner RL. The organization of the human striatum estimated by intrinsic functional connectivity. *Journal of neurophysiology*. 2012; 108:2242–2263. [PubMed: 22832566]
- Crittenden JR, Graybiel AM. Basal Ganglia disorders associated with imbalances in the striatal striosome and matrix compartments. *Frontiers in neuroanatomy*. 2011; 5:59. [PubMed: 21941467]
- Davis LK, Yu D, Keenan C, Gamazon E, Konkashbaev A, Derks EM, Neale BM, Yang J, Lee H, Evans P, et al. Partitioning the Heritability of Tourette Syndrome and Obsessive Compulsive Disorder Reveals Differences In Genetic Architecture. *PLoS Genetics*. 2013 (in press) in press.
- de Leeuw AS, Oranje B, van Meegen HJ, Kemner C, Westenberg HG. Sensory gating and sensorimotor gating in medication-free obsessive-compulsive disorder patients. *International clinical psychopharmacology*. 2010; 25:232–240. [PubMed: 20568657]
- Dere E, De Souza-Silva MA, Spieler RE, Lin JS, Ohtsu H, Haas HL, Huston JP. Changes in motoric, exploratory and emotional behaviours and neuronal acetylcholine content and 5-HT turnover in histidine decarboxylase-KO mice. *Eur J Neurosci*. 2004; 20:1051–1058. [PubMed: 15305873]
- Dere E, De Souza-Silva MA, Topic B, Spieler RE, Haas HL, Huston JP. Histidine-decarboxylase knockout mice show deficient nonreinforced episodic object memory, improved negatively reinforced water-maze performance, and increased neo- and ventro-striatal dopamine turnover. *Learn Mem*. 2003; 10:510–519. [PubMed: 14657262]
- Du JC, Chiu TF, Lee KM, Wu HL, Yang YC, Hsu SY, Sun CS, Hwang B, Leckman JF. Tourette syndrome in children: an updated review. *Pediatrics and neonatology*. 2010; 51:255–264. [PubMed: 20951354]
- Ellender TJ, Huerta-Ocampo I, Deisseroth K, Capogna M, Bolam JP. Differential modulation of excitatory and inhibitory striatal synaptic transmission by histamine. *The Journal of neuroscience : the official journal of the Society for Neuroscience*. 2011; 31:15340–15351. [PubMed: 22031880]
- Ercan-Sencicek AG, Stillman AA, Ghosh AK, Bilguvar K, O'Roak BJ, Mason CE, Abbott T, Gupta A, King RA, Pauls DL, et al. L-histidine decarboxylase and Tourette's syndrome. *N Engl J Med*. 2010; 362:1901–1908. [PubMed: 20445167]
- Fasano S, Pittenger C, Brambilla R. Inhibition of CREB activity in the dorsal portion of the striatum potentiates behavioral responses to drugs of abuse. *Front Behav Neurosci*. 2009; 3:29. [PubMed: 19826621]
- Fauchey V, Jaber M, Caron MG, Bloch B, Le Moine C. Differential regulation of the dopamine D1, D2 and D3 receptor gene expression and changes in the phenotype of the striatal neurons in mice lacking the dopamine transporter. *Eur J Neurosci*. 2000; 12:19–26. [PubMed: 10651856]
- Fernandez TV, Sanders SJ, Yurkiewicz IR, Ercan-Sencicek AG, Kim YS, Fishman DO, Raubeson MJ, Song Y, Yasuno K, Ho WS, et al. Rare copy number variants in tourette syndrome disrupt genes in histaminergic pathways and overlap with autism. *Biological psychiatry*. 2012; 71:392–402. [PubMed: 22169095]
- First, MB.; Spitzer, RL.; Gibbon, M.; Williams, JB. *Structured Clinical Interview for DSM-IV Axis I Disorders: Clinical Version (SCID-CV)*. American Psychiatric Press; Washington, DC: 1997.
- Flik G, Dremencov E, Cremers TI, Folgering JH, Westerink BH. The role of cortical and hypothalamic histamine-3 receptors in the modulation of central histamine neurotransmission: an in vivo electrophysiology and microdialysis study. *Eur J Neurosci*. 2011; 34:1747–1755. [PubMed: 22050612]

- Fray PJ, Sahakian BJ, Robbins TW, Koob GF, Iversen SD. An observational method for quantifying the behavioural effects of dopamine agonists: contrasting effects of d-amphetamine and apomorphine. *Psychopharmacology*. 1980; 69:253–259. [PubMed: 6774363]
- Graff-Guerrero A, Willeit M, Ginovart N, Mamo D, Mizrahi R, Rusjan P, Vitcu I, Seeman P, Wilson AA, Kapur S. Brain region binding of the D2/3 agonist [11C]-(+)-PHNO and the D2/3 antagonist [11C]raclopride in healthy humans. *Human brain mapping*. 2008; 29:400–410. [PubMed: 17497628]
- Graybiel AM. Habits, rituals, and the evaluative brain. *Annual review of neuroscience*. 2008; 31:359–387.
- Grillner S, Robertson B, Stephenson-Jones M. The evolutionary origin of the vertebrate basal ganglia and its role in action-selection. *The Journal of physiology*. 2013
- Haas HL, Sergeeva OA, Selbach O. Histamine in the nervous system. *Physiol Rev*. 2008; 88:1183–1241. [PubMed: 18626069]
- Haber SN, Knutson B. The reward circuit: linking primate anatomy and human imaging. *Neuropsychopharmacology*. 2010; 35:4–26. [PubMed: 19812543]
- Hoenig K, Hochrein A, Quednow BB, Maier W, Wagner M. Impaired prepulse inhibition of acoustic startle in obsessive-compulsive disorder. *Biol Psychiatry*. 2005; 57:1153–1158. [PubMed: 15866555]
- Ichise M, Toyama H, Innis RB, Carson RE. Strategies to improve neuroreceptor parameter estimation by linear regression analysis. *Journal of cerebral blood flow and metabolism*. 2002; 22:1271–1281. [PubMed: 12368666]
- Jankovic J, Kurlan R. Tourette syndrome: evolving concepts. *Mov Disord*. 2011; 26:1149–1156. [PubMed: 21484868]
- Joshi VV, Balsara JJ, Jadhav JH, Chandorkar AG. Effect of L-histidine and chlorcyclizine on apomorphine-induced climbing behaviour and methamphetamine stereotypy in mice. *European journal of pharmacology*. 1981; 69:499–502. [PubMed: 6113966]
- Kalivas PW. Histamine-induced arousal in the conscious and pentobarbital pretreated rat. *J Pharmacol Exp Ther*. 1982; 222:37–42. [PubMed: 7086707]
- Kamei C, Dabasaki T, Tasaka K. Cataleptic effect of histamine induced by intraventricular injection in mice. *Japanese journal of pharmacology*. 1983; 33:1081–1084. [PubMed: 6685788]
- Kamei C, Dabasaki T, Tasaka K. Effect of intraventricular injection of histamine on the pinna reflex in mice. *Japanese journal of pharmacology*. 1984; 35:193–195. [PubMed: 6146737]
- Kelley AE. Measurement of rodent stereotyped behavior. *Curr Protoc Neurosci*. 2001 Chapter 8, Unit 8.8.
- Kitanaka J, Kitanaka N, Tatsuta T, Miyoshi A, Koumoto A, Tanaka K, Nishiyama N, Morita Y, Takemura M. Pretreatment with l-histidine produces a shift from methamphetamine-induced stereotypical biting to persistent locomotion in mice. *Pharmacology, biochemistry, and behavior*. 2010; 94:464–470.
- Kitanaka J, Kitanaka N, Tatsuta T, Morita Y, Takemura M. Blockade of brain histamine metabolism alters methamphetamine-induced expression pattern of stereotypy in mice via histamine H1 receptors. *Neuroscience*. 2007; 147:765–777. [PubMed: 17570600]
- Kohl S, Heekeren K, Klosterkotter J, Kuhn J. Prepulse inhibition in psychiatric disorders - Apart from schizophrenia. *Journal of psychiatric research*. 2013; 47:445–452. [PubMed: 23287742]
- Krusong K, Ercan-Sencicek AG, Xu M, Ohtsu H, Anderson GM, State MW, Pittenger C. High levels of histidine decarboxylase in the striatum of mice and rats. *Neurosci Lett*. 2011; 495:110–114. [PubMed: 21440039]
- Kurlan R. Clinical practice. Tourette's Syndrome. *N Engl J Med*. 2010; 363:2332–2338.
- Kwak CH, Jankovic J. Tourettism and dystonia after subcortical stroke. *Movement disorders : official journal of the Movement Disorder Society*. 2002; 17:821–825. [PubMed: 12210884]
- Leckman JF, Bloch MH, Smith ME, Larabi D, Hampson M. Neurobiological substrates of Tourette's disorder. *J Child Adolesc Psychopharmacol*. 2010; 20:237–247. [PubMed: 20807062]
- Leckman JF, Riddle MA, Hardin MT, Ort SI, Swartz KL, Stevenson J, Cohen DJ. The Yale Global Tic Severity Scale: initial testing of a clinician-rated scale of tic severity. *J Am Acad Child Adolesc Psychiatry*. 1989; 28:566–573. [PubMed: 2768151]

- Lee AS, Duman RS, Pittenger C. A double dissociation revealing bidirectional competition between striatum and hippocampus during learning. *Proc Natl Acad Sci U S A*. 2008; 105:17163–17168. [PubMed: 18955704]
- Lipschitz DS, Mayes LM, Rasmussen AM, Anyan W, Billingslea E, Gueorguieva R, Southwick SM. Baseline and modulated acoustic startle responses in adolescent girls with posttraumatic stress disorder. *Journal of the American Academy of Child and Adolescent Psychiatry*. 2005; 44:807–814. [PubMed: 16034283]
- McCairn KW, Bronfeld M, Bebelovsky K, Bar-Gad I. The neurophysiological correlates of motor tics following focal striatal disinhibition. *Brain : a journal of neurology*. 2009; 132:2125–2138. [PubMed: 19506070]
- Mink JW. Neurobiology of basal ganglia circuits in Tourette syndrome: faulty inhibition of unwanted motor patterns? *Advances in neurology*. 2001; 85:113–122. [PubMed: 11530421]
- Narendran R, Slifstein M, Guillin O, Hwang Y, Hwang DR, Scher E, Reeder S, Rabiner E, Laruelle M. Dopamine (D2/3) receptor agonist positron emission tomography radiotracer [<sup>11</sup>C]-(+)-PHNO is a D3 receptor preferring agonist in vivo. *Synapse*. 2006; 60:485–495. [PubMed: 16952157]
- Nestler EJ, Hyman SE. Animal models of neuropsychiatric disorders. *Nat Neurosci*. 2010; 13:1161–1169. [PubMed: 20877280]
- O'Rourke JA, Scharf JM, Yu D, Pauls DL. The genetics of Tourette syndrome: a review. *J Psychosom Res*. 2009; 67:533–545. [PubMed: 19913658]
- Ohtsu H, Tanaka S, Terui T, Hori Y, Makabe-Kobayashi Y, Pejler G, Tchougounova E, Hellman L, Gertsenstein M, Hirasawa N, et al. Mice lacking histidine decarboxylase exhibit abnormal mast cells. *FEBS Lett*. 2001; 502:53–56. [PubMed: 11478947]
- Ondera, K.; Ogura, Y. *Advances in Histamine Research*. In: Uvnäs, B.; Tasaka, K., editors. *Advances in Histamine Research*. Pergamon Press; Oxford, UK: 1981. p. 127-136.
- Paul VN, Chopra K, Kulkarni SK. Modulation of motor functions involving central dopaminergic system by L-histidine. *Indian journal of experimental biology*. 2000; 38:988–993. [PubMed: 11324170]
- Payer DE, Behzadi A, Kish SJ, Houle S, Wilson AA, Rusjan PM, Tong J, Selby P, George TP, McCluskey T, et al. Heightened D Dopamine Receptor Levels in Cocaine Dependence and Contributions to the Addiction Behavioral Phenotype: A Positron Emission Tomography Study with [<sup>11</sup>C]-(+)-PHNO. *Neuropsychopharmacology*. 2013
- Pittenger C. Pathophysiological modeling of obsessive-compulsive disorder: challenges, and progress. *Biol Psychiatry*. 2011; 70:1002–1003. [PubMed: 22045035]
- Rabiner EA, Slifstein M, Nobrega J, Plisson C, Huiban M, Raymond R, Diwan M, Wilson AA, McCormick P, Gentile G, et al. In vivo quantification of regional dopamine-D3 receptor binding potential of (+)-PHNO: Studies in non-human primates and transgenic mice. *Synapse*. 2009; 63:782–793. [PubMed: 19489048]
- Rankin, ML.; Hazelood, LA.; Free, RB.; Namkung, Y.; Rex, EB.; Roof, RA.; Sibley, DR. *Molecular pharmacology of the dopamine receptors*. In: Iversen, LL.; Dunnett, SB.; Iversen, SD.; Bjorkund, A., editors. *The Dopamine Handbook*. Oxford University Press; New York: 2010. p. 63-87.
- Scharf JM, Yu D, Mathews CA, Neale BM, Stewart SE, Fagerness JA, Evans P, Gamazon E, Edlund CK, Service SK, et al. Genome-wide association study of Tourette's syndrome. *Molecular psychiatry*. 2012
- Schlicker E, Malinowska B, Kathmann M, Gothert M. Modulation of neurotransmitter release via histamine H3 heteroreceptors. *Fundam Clin Pharmacol*. 1994; 8:128–137. [PubMed: 8020871]
- Shmelkov SV, Hormigo A, Jing D, Proenca CC, Bath KG, Milde T, Shmelkov E, Kushner JS, Baljevic M, Dincheva I, et al. Slitrk5 deficiency impairs corticostriatal circuitry and leads to obsessive-compulsive-like behaviors in mice. *Nature medicine*. 2010; 16:598–602. 591p following 602.
- Singer HS, Szymanski S, Giuliano J, Yokoi F, Dogan AS, Brasic JR, Zhou Y, Grace AA, Wong DF. Elevated intrasynaptic dopamine release in Tourette's syndrome measured by PET. *Am J Psychiatry*. 2002; 159:1329–1336. [PubMed: 12153825]
- Stanwood GD, Artymyshyn RP, Kung MP, Kung HF, Lucki I, McGonigle P. Quantitative autoradiographic mapping of rat brain dopamine D3 binding with [(125)I]7-OH-PIPAT: evidence




- for the presence of D3 receptors on dopaminergic and nondopaminergic cell bodies and terminals. *J Pharmacol Exp Ther.* 2000a; 295:1223–1231. [PubMed: 11082459]
- Stanwood GD, Lucki I, McGonigle P. Differential regulation of dopamine D2 and D3 receptors by chronic drug treatments. *J Pharmacol Exp Ther.* 2000b; 295:1232–1240. [PubMed: 11082460]
- State MW. The genetics of Tourette disorder. *Curr Opin Genet Dev.* 2011
- Swerdlow NR. Update: Studies of prepulse inhibition of startle, with particular relevance to the pathophysiology or treatment of Tourette Syndrome. *Neuroscience and biobehavioral reviews.* 2012
- Swerdlow NR, Karban B, Ploum Y, Sharp R, Geyer MA, Eastvold A. Tactile prepuff inhibition of startle in children with Tourette's syndrome: in search of an “fMRI-friendly” startle paradigm. *Biol Psychiatry.* 2001; 50:578–585. [PubMed: 11690592]
- Takagi H, Morishima Y, Matsuyama T, Hayashi H, Watanabe T, Wada H. Histaminergic axons in the neostriatum and cerebral cortex of the rat: a correlated light and electron microscopic immunocytochemical study using histamine decarboxylase as a marker. *Brain Res.* 1986; 364:114–123. [PubMed: 3004646]
- Tellez LA, Medina S, Han W, Ferreira JG, Licona-Limon P, Ren X, Lam TT, Schwartz GJ, de Araujo IE. A gut lipid messenger links excess dietary fat to dopamine deficiency. *Science.* 2013; 341:800–802. [PubMed: 23950538]
- Terrados G, Finkernagel F, Stielow B, Sadic D, Neubert J, Herdt O, Krause M, Scharfe M, Jarek M, Suske G. Genome-wide localization and expression profiling establish Sp2 as a sequence-specific transcription factor regulating vitally important genes. *Nucleic acids research.* 2012; 40:7844–7857. [PubMed: 22684502]
- Traiffort E, Leurs R, Arrang JM, Tardivel-Lacombe J, Diaz J, Schwartz JC, Ruat M. Guinea pig histamine H1 receptor. I. Gene cloning, characterization, and tissue expression revealed by in situ hybridization. *Journal of neurochemistry.* 1994; 62:507–518. [PubMed: 8294913]
- Traiffort E, Vizuete ML, Tardivel-Lacombe J, Souil E, Schwartz JC, Ruat M. The guinea pig histamine H2 receptor: gene cloning, tissue expression and chromosomal localization of its human counterpart. *Biochemical and biophysical research communications.* 1995; 211:570–577. [PubMed: 7794271]
- Turetsky BI, Calkins ME, Light GA, Olincy A, Radant AD, Swerdlow NR. Neurophysiological endophenotypes of schizophrenia: the viability of selected candidate measures. *Schizophrenia bulletin.* 2007; 33:69–94. [PubMed: 17135482]
- Tziortzi AC, Searle GE, Tzimopoulou S, Salinas C, Beaver JD, Jenkinson M, Laruelle M, Rabiner EA, Gunn RN. Imaging dopamine receptors in humans with [<sup>11</sup>C]-(+)-PHNO: dissection of D3 signal and anatomy. *Neuroimage.* 2011; 54:264–277. [PubMed: 20600980]
- Volkow ND, Fowler JS, Wang GJ, Baler R, Telang F. Imaging dopamine's role in drug abuse and addiction. *Neuropharmacology* 56 Suppl. 2009; 1:3–8.
- Welch JM, Lu J, Rodriguiz RM, Trotta NC, Peca J, Ding JD, Feliciano C, Chen M, Adams JP, Luo J, et al. Cortico-striatal synaptic defects and OCD-like behaviours in Sapap3-mutant mice. *Nature.* 2007; 448:894–900. [PubMed: 17713528]
- White FJ, Wang RY. A10 dopamine neurons: role of autoreceptors in determining firing rate and sensitivity to dopamine agonists. *Life Sci.* 1984; 34:1161–1170. [PubMed: 6708722]
- Williams, K.; Bloch, MH.; State, M.; Pittenger, C. Tourette syndrome and tic disorders.. In: Charney, DS.; Nestler, EJ.; Sklar, P.; Buxbaum, JD., editors. *Neurobiology of Mental Illness.* 4th edition. Oxford University Press; New York: 2013.
- Wong DF, Brasic JR, Singer HS, Schretlen DJ, Kuwabara H, Zhou Y, Nandi A, Maris MA, Alexander M, Ye W, et al. Mechanisms of dopaminergic and serotonergic neurotransmission in Tourette syndrome: clues from an in vivo neurochemistry study with PET. *Neuropsychopharmacology.* 2008; 33:1239–1251. [PubMed: 17987065]
- Young ST, Porrino LJ, Iadarola MJ. Cocaine induces striatal c-fos immunoreactive proteins via dopaminergic D1 receptors. *Proc Natl Acad Sci U S A.* 1991; 88:1291–1295. [PubMed: 1825356]
- Zhou FW, Xu JJ, Zhao Y, LeDoux MS, Zhou FM. Opposite functions of histamine H1 and H2 receptors and H3 receptor in substantia nigra pars reticulata. *Journal of neurophysiology.* 2006; 96:1581–1591. [PubMed: 16738217]




**Figure 1. Reduced HA levels and stereotypy in *Hdc* knockout and haploinsufficient mice**

**A.** *Hdc* W317X was devoid of enzymatic activity; addition of equimolar *Hdc* W317X to a constant amount of wild-type *Hdc* mRNA reduced histamine accumulation, confirming the *in vitro* dominant-negative effect of this mutant. **B.** *Hdc* +/- and -/- mice showed reduced whole-tissue histamine in hypothalamus (left), striatum, and neocortex (right), confirming efficacy of the knockout and haploinsufficiency in +/- mice (n = 5 per genotype). **C.** All genotypes showed similar exploratory activity over 20 minutes in a novel open field. Following 8.5 mg/kg D-amphetamine (IP, in normal saline), WT mice showed locomotor activation, which was attenuated in -/- and +/- mice (RM-ANOVA, genotype,  $F[2,15] = 3.8$ ,  $p = 0.04$ ; time  $\times$  genotype,  $F[10,75] = 2.15$ ,  $p = 0.02$ ; n = 6 per genotype). **D.** Prior to amphetamine, KO mice showed normal rearing (upper panel) and center occupancy time (lower panel) in the open field, confirming normal exploratory activity and anxiety. **E.** KO mice showed markedly increased stereotypy, beginning 10 minutes after D-amphetamine injection. RM-ANOVA, genotype:  $F[2,15] = 3.8$ ;  $p = 0.04$ ; time  $\times$  genotype,  $F[10,75] = 1.83$ ,  $p = 0.06$ . **F.** At a higher dose of D-amphetamine (10 mg/kg), several -/- mice became completely immobile, making quantification of stereotypy impossible; +/- mice, however, now showed enhanced stereotypy (RM-ANOVA, genotype:  $F[1,10] = 7.70$ ,  $p = 0.01$ ; time  $\times$  genotype:  $F[5,50] = 4.36$ ,  $p = 0.002$ ; n = 6 per group). \*  $p < 0.05$ . See also Figure S1.




**Figure 2. Attenuation of tic-like stereotypies in *Hdc* +/- and -/- mice after pretreatment with haloperidol**

**A.** Experimental design. **B.** Haloperidol pretreatment produced a modest reduction in amphetamine-induced locomotion ( $F[2,22] = 6.86$ ,  $p = 0.005$ ) that did not vary by genotype (main effect of genotype:  $F[2,11] = 0.27$ ,  $p > 0.75$ ; genotype  $\times$  dose interaction:  $F[4,22] = 0.36$ ,  $p > 0.8$ ;  $n = 5$  mice per group). **C.** Tic-like stereotypy was again seen in *Hdc* +/- and -/- mice after saline pretreatment ( $n = 5$  mice per group; RM-ANOVA with genotype and treatment order as independent factors: main effect of genotype,  $F[2, 10] = 5.7$ ,  $p = 0.022$ ; main effect of time,  $F[5,50] = 5.7$ ,  $p < 0.001$ ; genotype  $\times$  time interaction,  $F[10,50] = 2.4$ ,  $p = 0.019$ ). **D.** Pretreatment with 0.3 mg/kg haloperidol attenuated the development of stereotypies. **E.** Pretreatment with 0.6 mg/kg haloperidol eliminated stereotypies in all genotypes (RM-ANOVA across all haloperidol doses: main effect of time,  $F[5,45] = 6.67$ ,  $p < 0.001$ ; main effect of haloperidol dose,  $F[2,18] = 4.42$ ,  $p = 0.027$ ; main effect of genotype,  $F[2,9] = 4.4$ ,  $p = 0.046$ ; genotype  $\times$  time,  $F[10,45] = 2.10$ ,  $p = 0.044$ ). **F.** Total stereotypies across the 30 minutes following amphetamine treatment are shown for each condition (RM-ANOVA: Main effect of genotype,  $F[2,9] = 4.39$ ,  $p = 0.046$ ; main effect of haloperidol treatment,  $F[2,18] = 4.42$ ,  $p = 0.027$ ). \*  $p < 0.05$  vs. wild-type, main effect or Bonferroni-corrected post-hoc.  $n = 5$  animals per genotype; see main text for detailed statistical analysis. See also Figure S2.




**Figure 3. Mitigation of stereotypies by histamine repletion**

**A,B.** Increased stereotypies were again seen after D-amphetamine, and were potentiated in *Hdc* *-/-* animals, in after ICV saline. These stereotypies were completely eliminated after HA infusion (20 µg). Saline groups: RM-ANOVA of genotype and treatment order, main effect of genotype,  $F[1,19] = 3.22$ ,  $p = 0.09$ , significant at alpha = 0.1 for a predicted directional effect; main effect of time,  $F[4,76] = 9.26$ ,  $p < 0.001$ ;  $n = 12$  mice of each genotype. See main text for analysis of HA effects. **C.** HA infusion led to reduced locomotor activation following amphetamine; however, this effect dissociated from the mitigation of stereotypies, as locomotor activity recovered in the second 30 minutes following amphetamine injection in *Hdc* *-/-* animals. \*  $p < 0.05$ ; \*\*  $p < 0.01$ ; x  $p < 0.05$  genotype effect. See also Figure S3.




**Figure 4. Impaired prepulse inhibition in humans and mice with deficient HDC activity**

**A.** Patients carrying the *Hdc* W317X mutation showed impaired PPI, measured 15 and 20 msec after the startle stimulus.  $N = 9$  *Hdc* W317X carriers, 9 matched controls. 1-tailed heteroskedastic t-test: 15 msec,  $t = 2.14$ ,  $p = 0.02$ ; 20 msec,  $t = 1.81$ ,  $p = 0.04$ . **B.** There was a weak negative association between PPI and age among the patients, but it did not reach statistical significance (data are shown for the 20 msec timepoint;  $p = 0.08$ ;  $p = 0.16$  at 15 msec). The association of PPI with age did not approach significance in controls. The effect of genotype on PPI remained significant after covarying for age (20 msec: main effect of genotype,  $F[1,15] = 4.45$ ,  $p = 0.05$ ; 15 msec: main effect of genotype,  $F[1,15] = 5.89$ ,  $p = 0.03$ ). **C.** *Hdc* +/- and -/- mice showed a deficit in tone PPI at three prepulse intensities. RM-ANOVA:  $F[2,31] = 4.50$ ;  $p = 0.019$ ;  $n = 12$  +/+, 16 +/-, 11 -/-. **D.** *Hdc* +/- and -/- mice showed enhanced startle, but the PPI phenotype was not explained by this increased startle.  $r = -0.643$ ;  $p < 0.001$ ; data shown are for the first PPI block; a similar effect was seen in the second block:  $r = -0.622$ ,  $p < 0.001$ . When analyzed separately, this correlation was seen in heterozygotes ( $n = 16$ ;  $r = -0.842$ ;  $p < 0.001$ ) and knockouts ( $n = 11$ ;  $r = 0.780$ ;  $p = 0.005$ ) but not in WT mice ( $n = 12$ ;  $r = -0.244$ ;  $p > 0.4$ ). RM-ANCOVA:  $F[2,35] = 6.67$ ;  $p = 0.004$ ; main effect of prepulse intensity:  $F[1,35] = 65.1$ ,  $p < 0.001$ . **E.** In a larger group of mice tested at different ages, the PPI phenotype did not change with age. RM-ANCOVA: main effect of genotype,  $F[2,56] = 3.79$ ,  $p = 0.03$ ; age,  $F[1,56] = 0.12$ ,  $p > 0.7$ ;  $n = 16$  +/+, 23 +/-, 23 -/-. **F.** This PPI phenotype was replicated when animals were tested in their dark phase. RM-ANOVA across the three prepulse intensities:  $F[2,72] = 8.0$ ,  $p = 0.001$ ;  $n = 21$  +/+, 26 +/-, 28 -/-. All data represented as mean  $\pm$  SEM. \*  $p < 0.05$ . See also Figure S4




### Figure 5. Histamine regulates striatal dopamine

**A.** HA (20  $\mu$ g) or saline was infused ICV into wild-type mice, as in Figure 3. DA in microdialysate from the contralateral striatum was markedly reduced, starting 20 min after HA administration.  $n = 7$  HA, 7 saline; RM-ANOVA: main effect of time,  $F[9,108] = 10.5$ ,  $p < 0.001$ ; main effect of HA,  $F[1,12] = 28.6$ ,  $p < 0.001$ ; time  $\times$  HA,  $F[9,108] = 3.9$ ,  $p < 0.001$ . **B.** HA in striatal microdialysate was dramatically reduced in *Hdc*  $-/-$  mice relative to controls. RM-ANOVA: main effect of genotype,  $F[1,14] = 6.60$ ,  $p = 0.02$ ; genotype  $\times$  time,  $F[7,98] = 4.23$ ,  $p < 0.001$ ;  $n = 8$  animals per group. **C.** Dopamine in striatal microdialysate showed a significant genotype by time interaction:  $F[9,126] = 2.70$ ,  $p = 0.007$ ;  $n = 8$  animals per group. **D.** Microdialysis data were normalized to the daytime baseline to reduce between-animal technical variability. The interaction was again apparent (main effect of genotype,  $F[1,14] = 2.99$ ,  $p = 0.11$ ; genotype  $\times$  time,  $F[9,126] = 2.85$ ,  $p = 0.004$ ); the genotype difference reached trend level across the final 4 timepoints (RM-ANOVA,  $F[1,14] = 3.8$ ,  $p = 0.07$ ) and significance across the final 2 ( $F[1,14] = 4.6$ ,  $p = 0.05$ ).  $\dagger p < 0.1$ ;  $* p < 0.05$ . All data represented as mean  $\pm$  SEM. See also Figure S5.




**Figure 6. Elevated striatal *Fos* expression in *Hdc*  $-/-$  mice is potentiated in striasomes by amphetamine**

**A,B.** *Fos*-positive cells (green) and  $\mu$ -opioid immunoreactivity (red), a marker of striasomes (patches), 45 minutes after 5 mg/kg D-amphetamine in a *Hdc*  $+/+$  mouse (**A**) and a *Hdc*  $-/-$  mouse (**B**). **C.** At baseline there was modestly but significantly increased *Fos* in *Hdc*  $-/-$  mice. RM-ANOVA, main effect of genotype,  $F[1,10] = 49.8$ ,  $p < 0.001$ ; effect of compartment and interaction NS;  $n = 6$  slices from each of 6 mice per genotype. **D.** After D-amphetamine there was increased *Fos* expression in both compartments (note y-axis scale), but much more prominently in striasomes; striasomal activation was specifically potentiated in *Hdc*  $-/-$  mice. RM-ANOVA: main effect of genotype,  $F[1,10] = 8.7$ ,  $p = 0.015$ ; main effect of compartment,  $F[1,10] = 207$ ,  $p < 0.0001$ ; interaction,  $F[1,10] = 6.29$ ,  $p = 0.03$ ;  $n = 2$  slices from each of 6 animals. Post-hoc genotype effects: \*  $p < 0.05$ ; \*\*  $p < 0.01$ .



**Figure 7. Elevated substantia nigra D2/D3 binding in *Hdc* W317X patients and HDC-KO mice**  
**A.** [<sup>11</sup>C]-PHNO binding potential (BP<sub>ND</sub>) in the striatum and globus pallidus (GP). Top row – structural MRI images for anatomical reference; second row – PHNO binding in TS patients carrying the *Hdc* W317X allele; bottom row – PHNO binding in matched control subjects (see Supplementary Table 2). **B.** [<sup>11</sup>C]-PHNO binding in more inferior, posterior, and medial sections, showing the GP and substantia nigra (SN). **C.** Patients carrying the *Hdc* W317X allele showed normal [<sup>11</sup>C]-PHNO binding in caudate and putamen, but elevated binding in GP and SN. RM-ANOVA: main effect of group: F[1,10] = 7.54; p = 0.035; main effect of region: F[3,30] = 33.48, p < 0.001; group × region interaction, F[3,30] = 6.85, p = 0.001. n = 3 *Hdc* W317X patients, 9 controls (see Table S2). **D.** Separation between patients and controls was particularly striking in SN. Mann-Whitney U test: p = 0.03. † uncorrected p < 0.05; \*\* uncorrected p < 0.01, significant after Bonferroni correction. See also Figure S6.





**Figure 8.**  
**A.** *Ex vivo* raclopride binding in SN of *Hdc* *+/+*, *+/-*, and *-/-* mice. **B.** Normalized SN binding was elevated in *Hdc* *+/-* and *-/-* mice relative to *+/+* controls. **C.** Binding correlated with the # of knockout alleles ( $r = 0.445$ ;  $\beta = 31.795$ ;  $p = 0.02$ ). **D.** Stronger raclopride binding was seen in striatum, reflecting the high density of D2 receptors there. **E.** Regression analysis across genotypes and caudal-rostral location showed a small but significant inverse relationship between dorsal striatal raclopride binding and # of HDC knockout alleles ( $\beta = -3.613$ ,  $p = 0.017$  for alleles;  $\beta = 6.01$ ,  $p < 0.001$  for R-C level). **F.** Raclopride binding in the mid-striatum (A-P levels 5-6), where the effect of genotype on binding was most pronounced, was negatively correlated with nigral raclopride binding in the same animals:  $r = -0.682$ ;  $p = 0.015$ . All data represented as individual data points or as mean  $\pm$  SEM. \*  $p < 0.05$ .  $n = 5$  *Hdc* *+/+* (12 SN slices, 23 str slices), 4 *Hdc* *+/-* (8 SN slices, 15 str slices), 6 *Hdc* *-/-* (8 SN slices from 4 mice; 21 str slices). See also Figure S6.

TABLE 1

Summary of parallel findings in TS patients carrying the *Hdc* W317X mutation and in *Hdc*  $-/-$  and  $+/-$  mice.

Characteristic	Patients w/ <i>Hdc</i> W317X mutation	<i>Hdc</i> $+/-$ & $-/-$ mice	Figure/Reference
<b>Histamine biosynthesis</b>	Reduced ( <i>in vitro</i> )	Reduced in tissue and striatal microdialysate	Ohtsu et al, 2001; Figure 1A, 1B, 5B
<b>Tics/stereotypy</b>	Motor, phonic tics	Potentiated stereotypy after threshold-dose amphetamine	Table 1; Figure 1E, F, 2B, 3A, B
<b>Prepulse inhibition</b>	Reduced	Reduced	Figure 4
<b>Striatal dopamine</b>	Not directly measured	Increased in active-phase microdialysate	Figure 5C, D
<b>Striatal dopamine signaling</b>	Not directly measured	Increased striatal <i>Fos</i> expression at baseline and after amphetamine	Figure 6
<b>Substantia nigra D2/D3 binding</b>	Increased by <i>in vivo</i> PHNO PET imaging	Increased by <i>in vitro</i> raclopride binding	Figure 7
<b>Dorsal striatal D2/D3 binding</b>	No evident change, by <i>in vivo</i> PHNO PET imaging	Modest decrease, by <i>in vitro</i> raclopride binding	Figure 8